JP2020520385A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020520385A5 JP2020520385A5 JP2020514327A JP2020514327A JP2020520385A5 JP 2020520385 A5 JP2020520385 A5 JP 2020520385A5 JP 2020514327 A JP2020514327 A JP 2020514327A JP 2020514327 A JP2020514327 A JP 2020514327A JP 2020520385 A5 JP2020520385 A5 JP 2020520385A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- compound
- paclitaxel
- combination
- carboplatin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 40
- 201000011510 cancer Diseases 0.000 claims 29
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 21
- 229960001592 Paclitaxel Drugs 0.000 claims 21
- 239000000203 mixture Substances 0.000 claims 20
- 229930003347 taxol Natural products 0.000 claims 19
- 229960004562 Carboplatin Drugs 0.000 claims 14
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 claims 14
- 239000003795 chemical substances by application Substances 0.000 claims 14
- 206010014733 Endometrial cancer Diseases 0.000 claims 9
- 229960004316 cisplatin Drugs 0.000 claims 9
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 claims 9
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 8
- 229960005277 gemcitabine Drugs 0.000 claims 8
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 6
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 6
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 5
- 229960003668 docetaxel Drugs 0.000 claims 5
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 4
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims 4
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 201000005202 lung cancer Diseases 0.000 claims 4
- 201000002528 pancreatic cancer Diseases 0.000 claims 4
- 206010029260 Neuroblastoma Diseases 0.000 claims 3
- 206010041823 Squamous cell carcinoma Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229940079593 drugs Drugs 0.000 claims 3
- 108010058566 130-nm albumin-bound paclitaxel Proteins 0.000 claims 2
- 206010004593 Bile duct cancer Diseases 0.000 claims 2
- 208000006990 Cholangiocarcinoma Diseases 0.000 claims 2
- 208000005017 Glioblastoma Diseases 0.000 claims 2
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 2
- 201000009030 carcinoma Diseases 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 239000003978 infusion fluid Substances 0.000 claims 2
- WBXPDJSOTKVWSJ-ZDUSSCGKSA-N pemetrexed Chemical compound C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 WBXPDJSOTKVWSJ-ZDUSSCGKSA-N 0.000 claims 2
- 229960005079 pemetrexed Drugs 0.000 claims 2
- ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 claims 1
- 208000009956 Adenocarcinoma Diseases 0.000 claims 1
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N Topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 229960000303 topotecan Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17382282.6 | 2017-05-16 | ||
| EP17382282 | 2017-05-16 | ||
| PCT/EP2018/062554 WO2018210830A1 (en) | 2017-05-16 | 2018-05-15 | A pharmaceutical combination for the treatment of a cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020520385A JP2020520385A (ja) | 2020-07-09 |
| JP2020520385A5 true JP2020520385A5 (US20070167479A1-20070719-C00034.png) | 2021-07-26 |
| JP7208650B2 JP7208650B2 (ja) | 2023-01-19 |
Family
ID=58765794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020514327A Active JP7208650B2 (ja) | 2017-05-16 | 2018-05-15 | 癌治療のための薬剤の組み合わせ |
Country Status (15)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114980879A (zh) | 2020-02-10 | 2022-08-30 | 能力制药公司 | 用于治疗癌症的药物组合 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63258816A (ja) * | 1987-04-16 | 1988-10-26 | Nippon Oil & Fats Co Ltd | 抗癌剤組成物 |
| CA2010511A1 (en) * | 1989-03-01 | 1990-09-01 | Roberto L. Ceriani | Method of enhancing cancer therapy by administration of unsaturated fatty acids |
| GB9618420D0 (en) * | 1996-09-04 | 1996-10-16 | Scotia Holdings Plc | Fatty acid treatment |
| EP1214067A1 (en) * | 1999-09-09 | 2002-06-19 | EFA Sciences Llc | Methods for treating cell proliferative disorders including cancer |
| ES2345241B1 (es) * | 2009-03-16 | 2011-09-08 | Lipopharma Therapeutics | Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos. |
| ES2401629B1 (es) * | 2011-10-07 | 2014-03-04 | Universitat De Les Illes Balears | Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos. |
-
2018
- 2018-05-15 BR BR112019023944A patent/BR112019023944A2/pt active Search and Examination
- 2018-05-15 MX MX2019013683A patent/MX2019013683A/es unknown
- 2018-05-15 EP EP23179349.8A patent/EP4234035A3/en active Pending
- 2018-05-15 WO PCT/EP2018/062554 patent/WO2018210830A1/en active Application Filing
- 2018-05-15 CA CA3063625A patent/CA3063625A1/en active Pending
- 2018-05-15 US US16/614,084 patent/US11260042B2/en active Active
- 2018-05-15 JP JP2020514327A patent/JP7208650B2/ja active Active
- 2018-05-15 AU AU2018269462A patent/AU2018269462B2/en active Active
- 2018-05-15 KR KR1020197034996A patent/KR102569052B1/ko active IP Right Grant
- 2018-05-15 CN CN201880032629.0A patent/CN110636842A/zh active Pending
- 2018-05-15 ES ES18722621T patent/ES2955524T3/es active Active
- 2018-05-15 PL PL18722621.2T patent/PL3624786T3/pl unknown
- 2018-05-15 EP EP18722621.2A patent/EP3624786B1/en active Active
- 2018-05-15 HU HUE18722621A patent/HUE063275T2/hu unknown
-
2019
- 2019-11-01 ZA ZA2019/07286A patent/ZA201907286B/en unknown
- 2019-11-15 CL CL2019003288A patent/CL2019003288A1/es unknown
-
2022
- 2022-01-21 US US17/581,587 patent/US20220257554A1/en active Pending
